Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 11, 2002, Pages 1663-1702

  Li, Qun ^a   Sham, Hing L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 289099; A 293620; A 3181315; ABT 751; AC 7700; AC 7739; AM 132; Anhydrovinblastine; Antiangiogenesis; Anticancer; Antimitotic; Antitubulin; Antitumour; AVE8062A; AVE8063A; Cemadotin; CF248; CI 980; COBRA 1; Colchicine; Combretastatin; Cryptophycin; Curacin; D 24851; D 68144; D 82318; Dolastatin; DZ 3358; E7010; E7070; E7820; Eg265; ER 34410; Estramusine; Ethoxyoestradiol; Halichondrin; Halimide; Hemiasterlin; HMN 154; HTI 286; ILX651; Kinesin; KSP; LS 4559; LS 4577; LU223651; MHM 214; Microtubule; Multi drug resistance (MDR); Myoservin; Noscapine; NSC 664171; Oncocidine A1; P glycoprotein; Phenstatin; Phenylahistin; Phosphate prodrug; Ro 31,7453; RPR112378; RPR115781; SB 715992; SPIKET P; Sulfonamide; T138067; T900607; Tubulin; TZT 1027; Vinblastine; Vinca alkaloid; Vincristine; Vindesine; Vinflunine; Vinorelbine; ZD6126; ZD6474

Indexed keywords

A 105972; ALLOCHOLCHINOL PHOSPHATE; ANTIMITOTIC AGENT; CISPLATIN DERIVATIVE; COLCHICINE DERIVATIVE; COMBRETASTATIN A4; DEACETAMIDOCOLCHICINE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; GAMMA TUBULIN; IMIDAZOLE; INTRADOSE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OXADIAZOLE DERIVATIVE; OXAZOLE; OXAZOLONE; PACLITAXEL; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE; QUINOLONE DERIVATIVE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SULFONAMIDE; TAXANE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; THIOCOLCHICINE; TROPONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINCA ALKALOID; ZM 445526;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IC 50; MAXIMUM TOLERATED DOSE; METAPHASE; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN INTERACTION; REVIEW;

EID: 0036850914     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.11.1663     Document Type: Review

References (265)

1. NOGALES E: Structural insight into microtubule function. Ann. Rev. Biophys. Biomol. Struct. (2001) 30:397-420.
2. LÖWE J, LI H, DOWNING KH, NOGALES E: Refined structure of αβ-tubulin at 3.5 Å resolution. J. Mol. Biol. (2001) 313:1045-1057.
3. FORD HJ, PARDEE AB: Cancer and cell cycle. J. Cell. Biochem. (1999) 32/33 (Suppl.):166-172.
4. JORDAN MA, WILSON L: Use of drugs to study role of microtubule assembly dynamics in living cells. In: Methods in Enzymology. Vallee R (Ed.), Academic Press, London (1998) 298:252-276.
5. DOWNING KH: Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Ann. Rev. Cell. Dev. Biology (2000) 16:89-111.
6. TRAXLER P, BOLD G, BUCHDUNGER E et al.: Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. (2001) 21:499-512.
7. BASELGA J, AVERBUCH SD: ZD1839 ('Iressa') as an anticancer agent. Drugs (2000) 60(suppl.1):33-40.
8. DUMONTET C: Mechanisms of action and resistance to tubulin-binding agents. Fxp. Opin. Invest. Drugs (2000) 9:779-788.
9. BURKHART CA, KAVALLARIS M, BAND HORWITZ S: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta (2001) 1471:1-9.
10. LI Q, SHAM HL, ROSENBERG SH: Antimitotic agents. Ann. Rep. Med. Chem. (1999) 34:139-148.
11. VON ANGERER E: New inhibitors of tubulin polymerisation. Exp. Opin. Ther. Patents (1999) 9:1069-1081.
12. LEE KH: Novel antitumor agents from higher plants. Med. Res. Rev. (1999) 19:569-596.
13. LEE KH: Anticancer drug design based on plant-derived natural products. J. Biomed. Sci. (1999) 6:236-250.
14. NISHIO K, SAIJO N: Cytoskeletons and and mitotic agents developed in Japan. Anticancer Drug Des. (1999) 14:133-141.
15. SHI Q, CHEN K, MORRISNATSCHKE SL, LEE KH: Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr. Pharm. Des. (1998) 4:219-248.
16. IWASAKI S: Natural organic compounds that affect microtubule functions. J. Pharm. Soc. Jpn. (1998) 118:111-126.
17. JORDAN A, HADFIELD JA, LAWRENCE NJ, MCGOWN AT: Tubulin as a target for anticancer drugs - agents which interact with the mitotic spindle. Med. Res. Rev. (1998) 18:259-296.
18. GUHA S, BHATTACHARYYA B: The colchicine-tubulin interaction - a review. Curr. Sci. (1997) 73:351-358.
19. BAI R. COVELL DG, PEI XF et al.: Mapping the binding site of colchicinoids on β-tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. J. Biol. Chem. (2000) 275:40443-40452.
20. JANIK ME, BANE SL: Synthesis and antimicrotubule activity of combretatropone derivatives. Bioorg. Med. Chem. (2002) 10:1895-1903.
21. GUAN J, ZHU XK, TACHIBANA Y et al.: Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors. J. Med. Chem. (1998) 41:1956-1961.
22. GELMI MI, MOTTADELLI S, POCAR D et al.: N-deacetyl-N-aminoacylthiocolchicine derivatives: synthesis and biological evaluation on MDR-positive and MDR-negative human cancer cell lines. J. Med. Chem. (1999) 42:5272-5276.
23. MILLER TA, BULMAN AL, THOMPSON CD, MACDONALD TL: The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg. Med. Chem. Lett. (1999) 9:407-412.
24. BRECHT R, SEITZ G, GUENARD D, THORET S: Novel allocolchicinoids with an eight membered B ring: design, synthesis and inhibition of tubulin assembly. Bioorg. Med. Chem. (2000) 8:557-562.
25. GUAN J, ZHU XK, BROSSI A et al.: Antitumor agents. 192. Antitubulin effect and cytotoxicity of C(7)-oxygenated allocolchicinoids. Coll. Czech. Chem. Comm. (1999) 64:217-228.
26. DAVIS PD, HILL SA, GALBRAITH SM et al.: ZD6126: A new agent causing selective damage of tumour vasculature. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 2085.
27. DAVIS PD, HILL SA, CHAPLIN DJ, BLAKEY DC: Comparison of the antitumour activity of ZD6126 administered by different routes. 92nd Annual Meeting of American Association for Cancer Research. New Orleanes, USA (2001): Abstract 4419.
28. BLAKEY DC, ASHTON SE, EARDLEY SE et al.: ZD6126: a novel vascular targeting agent which causes massive necrosis in a range of human tumour xenograft model. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 2086.
29. GOTO H, YANO S, ZHANG H et al.: Activity of a new vascular-targeting agent, CD6126, in pulmonary metastases from human lung adenocarcinoma in nude mice. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 777.
30. BLAKEY DC, WESTWOOD FR, ASHTON SE: Vascular targeting activity of ZD6126 in two tumour models growing in athymic rats. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 4421.
31. EVELHOCH JL, HE Z, POLIN L et al.: MRI evaluation of the effects of ZD6126 on tumor vasculture. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 580.
32. BLAKEY DC, ASHTON SE, WESTWOOD FR, RYAN A: Optimisation of ZD6126 activity in the Galu-6 tumor model. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 778.
33. SIEMANN DW, LEPLER S, ROJIANI A: The novel vascular-targeting agent ZD6126 enhances the anti-tumor efficacy of cisplatin. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 2594.
34. WEDGE SR, KENDREW J, OGILVIE DJ et al.: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. 93rd Annual Meeting of American Association for Cancer Raearch. San Francisco, USA (2002): Abstract 5351.
35. ARNOULD JC, BIRD TG, ASHTON SE, BLAKEY DC, DAVIS PD: Novel vascular targeting agents: amino colchicinol derivatives of ZD6126. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 4426.
36. XIA Y, YANG ZY, XIA P et al.: Antitumor agents - 181 - synthesis and biological evaluation of 6,7,2′,3′, 4′-substituted-1,2, 3,4-tetrahydro-2- phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. (1998) 41:1155-1162.
37. GRIGGS J, METCALFE JC, HESKETH R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. (2001) 2:82-87.
38. OHSUMI K, NAKAGAWA R, FUKUDA Y et al.: Novel combretastatin analogues effective against murine solid tumors - design and structure-activity relationships. J. Med. Chem. (1998) 41:3022-3032.
39. TOZER GM, PRISE VE, WILSON J et al.: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59:1626-1634.
40. TOZER GM, PRISE VE, WILSON J et al.: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. (2001) 61:6413-6422.
41. BEAUREGARD DA, HILL SA, CHAPLIN DJ, BRINDLE KM: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. (2001) 61:6811-6815.
42. IWASAKI S, SHIRAI R: Natural organic compounds that affect microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin. J. Pharm. Soc. Jpn (2000) 120:875-889.
43. LIN CM, SINGH SB, CHU PS et al.: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. (1988) 34:200-208.
44. MAYA AB, DEL REY B, LAMAMIE DE CLAIRAC RP et al.: Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. (2000) 10:2549-2551.
45. HADFIELD JA, MCGOWN AT: Preparation and evaluation of diarylalkynes as antitumour agents. Synth. Commun. (1998) 28:1421-1431.
46. PETTIT GR, LIPPERT JW III: Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Des. (2000) 15:203-216.
47. PETTIT GR, MINARDI MD, BOYD MR, PETTIT RK: Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs. Anti-Cancer Drug Des. (2000) 15:397-403.
48. HOLWELL SE, COOPER PA, GROSIOS K et al.: Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res. (2002) 22:707-711.
49. PINNEY KG, TANPURE RP: Triarylethylene ligands which incorporate structural motifs reminiscent of combretastatin A-4 and tamoxifan: synthesis and biological evaluation as tubulin binding compounds. 222nd ACS Meeting. Chicago, USA (2001): MEDI68.
50. OHSUMI K, HATANAKA T, NAKAGAWA R et al.: Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anti-Cancer Drug Des. (1999) 14:539-548.
51. NIHEI Y, SUGA Y, MORINAGA Y et al.: A novel combretastatin A-4 derivative, AC7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. (1999) 90:1016-1025.
52. NIHEI Y, SUZUKI M, OKANO A et al.: Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn. J. Cancer Res. (1999) 90:1387-1395.
53. HORI K, SAITO S, SATO Y, KUBOTA K: Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monitor (2001) 7:26-33.
54. HORI K, SAITO S, NIHEI Y, SUZUKI M, SATO Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn. J. Cancer Res. (1999) 90:1026-1038.
55. ARCHIMBAUD Y, FRASCHINI MC et al.: Mouse plasma and tumour pharmacokinetics of AVE8062, a new combretastatin. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 779.
56. BISSERY MC, LEJEUNE P, VRIGNAUD P: In vivo evaluation of AVE8062A, a compound active on the tumor vasculature. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 780.
57. LEJEUNE P, HODGE TG, VRIGNAUD P, BISSERY MC: In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 781.
58. HATANAKA T, FUJITA K, OHSUMI K et al.: Novel B ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Med. Chem. Lett. (1998) 8:3371-3374.
59. PETTIT GR, TOKI BE, HERALD DL et al.: Antineoplastic agents. 410. Asymmetric hydroxylation of transcombretastatin A-4. J. Med. Chem. (1999) 42:1459-1465.
60. PETTIT GR, LIPPERT JW III, HERALD DL, HAMEL E, PETTIT RK: Antineoplastic agents 440. Asymmetric synthesis and evaluation of the combretastatin A-1 SAR probes (1S,2S)- and (1R,2R)-1, 2-dihydroxy-1-(2m,3′-dihydroxy-4 pm-methoxyphenyl)-2- (3′′,4′′,5′m-trimethoxyphenyl)-ethane. J. Nat. Prod. (2000) 63:969-974.
61. SHIRAI R, TAKAYAMA H, NISHIKAWA A, KOISO Y, HASHIMOTO Y: Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg. Med. Chem. Lett. (1998) 8:1997-2000.
62. PETTIT GR, LIPPERT JW III, BOYD MR, VERDIER-PINARD R HAMEL E: Antineoplastic agents 442. Synthesis and biological activities of dioxostatin. Anti-Cancer Drug Des. (2000) 15:361-371.
63. SHIRAI R, OKABE T, IWASAKI S: Synthesis of comformationally restricted combretastatins. Heterocycles (1997) 46:145-148.
64. WANG L, WOODS KW, LI Q et al.: Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem (2002) 45:1697-1711.
65. OHSUMI K, HATANAKA T, FUJITA K et al.: Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett. (1998) 8:3153-3158.
66. NAM NH, KIM Y, YOU YJ, HONG DH, KIM HM, AHN BZ: Combretoxazolones: Synthesis, cytotoxicity and antitumor activity. Bioorg. Med. Chem. Lett. (2001) 11:3073-3076.
67. KIM Y, NAM NH, YOU YJ, AHN BZ: Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. Bioorg. Med Chem. Lett. (2002) 12:719-722.
68. FLYNN BL, FLYNN GP, HAMEL E, JUNG MK: The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. (2001) 11:2341-2343.
69. FLYNN BL, VERDIER-PINARD P, HAMEL E: A novel palladium-mediated coupling approach to 2,3-disubstituted benzo[b]thiophenes and its application to the synthesis of tubulin binding agents. Org. Lett. (2001) 3:651-654.
70. BANWELL MG, FLYNN BL, WILLIS AC, HAMEL E: Synthesis, X-ray crystal structure and tubulin-binding properties of a benzofuran analogue of the potent cytotoxic agent combretastatin A4. Aust. J. Chem. (1999) 52:767-774.
71. TAHIR SK, HAN EKH, CREDO B et al.: A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. (2001) 61:5480-5485.
72. WU-WONG JR, ALDER JD, ALDER L, et al.: Identification and characterization of A-105972, an antineoplastic agent. Cancer Res. (2001) 61:1486-1492.
73. SZCZEPANKIEWICZ BG, LIU G, JAE HS et al.: New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. J. Med. Chem. (2001) 44:4416-4430.
74. LAWRENCE NJ, RENNISON D, WOO M, MCGOWN AT, HADFIELD JA: Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers Bioorg. Me. Chem. Lett. (2001) 11:51-5
75. WOODS KW, MCCROSKEY RW, STEINER BA et al.: Sulfur containing double bond replacement of combretastatin A-4 as antimitotic agents. 221st ACS Meeting. San Diego, USA (2001): MEDI138.
76. PETTIT GR, TOKI B, HERALD DL et al.: Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem. (1998) 41:1688-1695.
77. PETTIT GR, GREALISH MP, HERALD DL, BOYD MR, HAMEL E, PETTIT RK: Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. J. Med. Chem. (2000) 43:2731-2737.
78. ALEKSANDRZAK K, MCGOWN AT, HADFIELD JA: Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4. Anti-Cancer Drugs (1998) 9:545-550.
79. GHATAK A, DORSEY J, GARNER CM, MOCHARLA VP, CHEN Z, PINNEY KG: Studies in anticancer compounds: synthesis of 6-methsoxy-1-(3′, 4′, 5′-trimethoxyphenyl-3,4-dihydronaphthalene further functionalized at C-5 or C-7. 222nd ACS Meeting. Chicago, USA (2001): ORGN153.
80. DAMAYANTHI Y, LOWN JW: Podophyllotoxins: current status and recent developments. Curr. Med. Chem. (1998) 5:205-252.
81. LI Q STEINER BA, WOODS KW et al.: Synthesis and biological evaluation of diarylsulfonamides as tubulin polymerisation inhibitors. Discovery of A-318315 and A293620 as orally and intravenously active antitumor agents. 93rd Annual Meeting of American Association for Cancer Research 2002. San Francisco, USA (2002). Abstract 1313.
82. GWALTNEY SL, II, IMADE HM, LI Q et al.: Novel sulfonate derivatives: potent antimitotic agents. Bioorg. Med. Chem. Lett. (2001) 11:1671-1673.
83. GWALTNEY SL, II, IMADE HM, BARR KJ et al.: Novel sulfonate analogues of combretastatin A-4: Potent antimitotic agents. Bioorg. Med. Chem. Lett. (2001) 11:871-874.
84. OWA T, NAGASU T: Novel sulphonamide derivatives for the treatment of cancer. Exp. Opin. Ther. Patents (2000) 10:1725-1740.
85. YOSHIMATSU K, YAMAGUCHI A, YOSHINO H, KOYANAGI N, KITOH K: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. (1997) 57:3208-3213.
86. IWAMOTO Y, NISHIO K, FUKUMOTO H, YOSHIMATSU K, YAMAKIDO M, SAIJO N: Preferential binding of E7010 to murine β3-tubulin and decreased β3-tubulin in E7010-resistant cell lines. Jpn. J. Cancer. Res. (1998) 89:954-962.
87. ZIELINSKI MOZNY NA, NUKKALA MA, WILSON ST et al.: Biological activity of ABT-751: an oral antimitotic agent. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 1323.
88. YOSHINO H, NORIHIRO U, NIIJIMA J et al.: Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem. (1994) 35:2496-2497.
89. FUNAHASHI Y. KOYANAGI N, KITOH K: Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted routine Colon 38 tumor. Cancer Chemother. Pharmacol. (2001) 47:179-184.
90. SEGRETI J, POLAKOWSKI J, DIERKS K et al.: Selective effect of the novel antimitotic compound ABT-751 on tumor vasculature: an in vivo rat hemodynamic study. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 783.
91. LUO Y, MOHNING KM, NUSS ME et al.: A novel anti-tubulin agent (ABT-751) selectively reduces tumour perfusion in a subcutaneous rat tumour model as measured by MRI. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 784.
92. YAMAMOTO K, NODA K, YOSHIMURA A, FUKUOKA M, FURUSE K, NIITANI H: Phase I study of E7010. Cancer Chemother. Pharmacol. (1998) 42:127-134.
93. UEDA N, TSUKAHARA N, WATANABE T et al.: ER-34410, a structurally novel sulfonamide as a potential injectable antitumor agent. Proc. Am. Assoc. Cancer Res. (1995) 36:Abstract 2290.
94. KATOH F, HONMURA T, YAMAGUCHI R, MATSUDA M, KIMURA K, HIDAKA H: HMN-214, a novel antitumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (1997) 38:Abstract 473.
95. KATOK F, TAKAGI M, KITAZAWA C et al.: Mode of mechanisms of cell death induced by HMN-214, a novel antitumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (1998) 39:Abstract 225.
96. TANAKA H, OHSHIMA N, HIKADA H: Apoptosis induction by novel anti-cancer compound, HMN-154 (HMN-176) through suppressing the expression of cell cycle controllers. Proc. Am. Assoc. Cancer Res. (1998) 39-Abstract 319.
97. TANAKA H, OHSHIMA N, HIDAKA H: Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol. Pharmacol. (1999) 55:356-363.
98. TAYLOR C, DRAGOVICH T, SIMPSON A, VON HOFF D: A Phase I and pharmakokinetic study of HMN-214 administered orally for 21 consecutive days, repeated every 28 days to patients with advanced solid tumours. 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 419.
99. PATNAIK A, FORERO L, TOLCHERAW et al.: A Phase I and pharmacokinetic (PK) study of HMN-214, an oral antimitotubular agent with polo-like and cyclin-dependent kinase inhibitory activities. 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 418.
100. WANG HK, XIA Y, YANG ZY, NATSCHKE SL, LEE KH: Recent advances in the discovery and development of flavonoids and their analogues as antitumor and and-HIV agents. Adv. Exper. Med. Biol. (1998) 439:191-225.
101. BEUTLER JA, HAMEL E, VLIETINCK AJ et al.: Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J. Med. Chem. (1998) 41:2333-2338.
102. POBST J, KUFFEL MJ, ARNT CR: Aminoflavone (NSC 686288) induction of vytochrome P450 1A1 in sensitive human cell lines is associated with metabolic activation, DNA damage and antiproliferative activity. Clin. Cancer Res. (2001) 7(Suppl.):3797.
103. LOAIZA PEREZ AI, VISTICA D, KENNEY S et al.: The aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent NSC 686288. Clin. Cancer Res. (2001) 7(Suppl.):3737.
104. BROWN AP, MORRISEY RL, RODVOLD KA et al.: Intravenous plasma elimination kinetics and toxicity of an aminoflavone in the dog. Proc. Am. Assoc. Cancer Res. (1999) 40-Abstract 390.
105. ALLEY MC, STINSON SF, PACULA COX CM et al.: Pharmacologic evaluations of a novel amino-substituted flavone (NSC 686288) exhibiting unique in vitro and in vivo anticancer activities. Proc. Am. Assoc. Cancer Res. (1999) 40:Abstract 119.
106. DYKES DJ, HOLLINGSHEAD DJ, CAMALIER RF, MAYO JG, SAUSVILLE EA: Marked activity of an aminoflavone (NSC-686288) against human renal tumors in athymic nude mice. Proc. Am. Assoc. Cancer Res. (1999) 40:Abstract 118.
107. PIETERS L, VAN DYCK S, GAO M et al.: Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerisation. J. Med. Chem. (1999) 42:5475-5481.
108. XIA Y, YANG ZY, MORRIS-NATSCHKE SL, LEE KH: Recent advances in the discovery and development of quinolones and analogs as antitumor agents. Curr. Med. Chem. (1999) 6:179-194.
109. LI L, WANG HK, KUO SC et al.: Antitumor agents. 155. Synthesis and biological evaluation of 3′,6,7-substituted 2-phenyl-4-quinolones as antimicrorubule agents. J. Med. Chem. (1994) 37:3400-3407.
110. XIA Y, YANG ZY, XIA P et al.: Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J. Med. Chem. (2001) 44:3932-3936.
111. ZHANG SY, BASTOW KF, TACHIBANA Y et al.: Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerisation. J. Med. Chem. (1999) 42:4081-4087.
112. XIA Y. YANG ZY, HOUR MJ et al.: Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioarg. Med. Chem. Lett. (2001) 11:1193-1196.
113. HOUR MJ, HUANG LJ, KUO SC et al.: 6-Alkylamino- and 2,3-dihydro-3′-methoxy-2- phenyl-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerisation. J. Med. Chem. (2000) 43:4479-4487.
114. LI Q, WOODS KW, CLAIBORNE A et al.: Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerisation inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg. Med. Chem. Lett. (2002) 12:465-469.
115. TAHIR SK, NUKKALA MA, ZIELENIEWSKI MOZNY NA et al.: Biological activity of A-289099: an indoleoxazoline derivative with antimitotic activity. 93d Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 1315.
116. ZIELENIEWSKI MOZNY NA, CREDO RB, TAHIR SK et al.: Biological efficacy of A-318315: an orally active antimitotic agent. 93d Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 1314.
117. MEDARDE M, RAMOS A, CABALLERO E et al.: Synthesis and antineoplastic activity of combretastatin analogues - heterocombretastatins. Eur. J. Med. Chem. (1998) 33:71-77.
118. OWA T, YOSHINO H, OKAUCHI T et al.: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. (1999) 42:3789-3799.
119. FUKUOKA K, USUDA J, IWAMOTO Y et al.: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs (2001) 19:219-227.
120. OZAWA Y, SUGI NH, NAGASU T et al.: E7070, a novel sulfonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer (2001) 37:2275-2282.
121. PUNT CJ, FUMOLEAU P, VAN DE WALLE B, FABER MN, RAVIC M, CAMPONE M: Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol. (2001) 12:1289-1293.
122. VAN KESTEREN C, MATHOT RA, RAYMOND E et al.: Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four Phase I studies. Br. J. Clin. Pharmacol. (2002) 53:553P
123. FUNAHASHI Y, SUGI NH, HANEDA T et al.: Cell and tumor biology 38: angiogenesis inhibitors IV: novel inhibitors. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 4093.
124. SEMABA T, FUNAHASHI Y, YAMAMOTO Y et al.: A novel angiogenesis inhibitor, ER-68203-00, II. Anti-angiogenesis potency and therapeutic efficacy in tumor xenograf models. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 4094.
125. ONO N, SEMBA T, HOSHI SS et al.: Angiogenesis inhibitor, E7820; enhancement of anti-angiogenic activity through the combination with receptor kinase inhibitors of VEGF or BFGF. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 912.
126. FOTOUHI N, AHMAD M, BANNER B et al.: Synthesis and structure-activity relationship of bis-indolylmaleimides as cell cycle inhibitors: elaboration of the development candidate, Ro 31-7453. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002) Abstract 3655.
127. KONG N, SPECIAN JR. A, LOVEY A et al.: Design and synthesis of novel orally bioavailable bisindolyl maleimides as cell cycle inhibitors. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 3656.
128. RITLAND S, STEELE T, KEN R et al.: Preclinical characterization of Ro 31-7453. 92nd Annual Meeting of American Association for Cancer Research; New Orleans, USA (2001). Abstract 4893.
129. NICOLSON M, BISSET D, CASSIDY J et al.: A Phase I clinical and pharmacokinetic study of oral Ro 31-7453, a novel cell cycle inhibitor, administered in combination with gemcitabine. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 1369.
130. MEDARDE M, RAMOS AC, CABALLERO E et al.: Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. (1999) 9:2303-2308.
131. GOLDBRUNNER M, LOIDL G, POLOSSEK T, MANNSCHRECK A, VON ANGERER E: Inhibition of tubulin polymerisation by 5,6-dihydroindolo. J. Med. Chem. (1997) 40:3524-3533.
132. GASTPAR R, GOLDBRUNNER M, MARKO D, VON ANGERER E: Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerisation. J. Med. Chem. (1998) 41:4965-4972.
133. MAHBOOBI S, PONGRATZ H, HUFS KY H et al.: Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. (2001) 44:4535-4553.
134. MCGOWN AT, FOX BW: Interaction of the novel agent amphethinile with tubulin. Br. J. Cancer (1989) 59:865-868.
135. BACHER G, NICKEL B, EMIG P et al.: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity, Cancer Res. (2001) 61:392-399.
136. NICHEL B, SCHMIDT M, DREVS J et al.: Potent in vivo antitumor activity of D-24851, a novel tubulin inhibitor, in human xenografts and antimetastatic effect in the renca model. 92nd Annual Meeting of American Association for Cancer Research. New Orleanes, USA (2001): Abstract 1992.
137. GÜNTHER E, EMIG P, REICHERT D et al.: Discovery and synthesis of novel N-substituted indolyl-3-glyoxylic acid derivatives with tubulin-binding activity as anticancer agents. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 4888.
138. MEDINA JC, SHAN B, BECKMANN H et al.: Novel Antineoplastic agents with efficacy against multidrug resistant tumour cells. Bioorg. Med. Chem. Lett. (1998) 8:2653-2656.
139. YE Q, FRANKMOELLE W, LE H, WRIGHT R, TIMMERMANS PB: Identification and detection of T138067 metabolites formed in vitro in the presence of rat hepatic subcellular fractions and in vivo in humans. 91st Annual Meeting of American Association for Cancer Research San Francisco, USA (2000): Abstract 1380.
140. SHAN B, MEDINA JC, SANTHA E et al.: Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl. Acad. Sci. USA (1999) 96:5686-5691.
141. MEDINA JC, ROCHE D, SHAN B et al.: Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg. Med. Chem. Lett. (1999) 9:1843-1846.
142. FRANKMOELLE WP, MEDINA JC, SHAN B, NARBUT MR, BECKMANN H: Glurathione S-transferase metabolism of the antineoplastic pentafluorophenylsulfonamide in tissue culture and mice. Drug Metabolism Disposition (2000) 28:951-958.
143. MOLPUS K, SCHWARTZ G, O'DWYER P et al.: A Phase I study of anti-microtubule agent T138067-sodium administered daily x 5 every 3 weeks. 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 415.
144. LEUNG TWT, FEUN L, POSEY J, STAGG RJ, LEVY MD, VENOOK AP: A Phase II study of T138067-sodium in patients (pts) with unresectable hepatocellular carcinoma. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 572.
145. JAHAN TM, SANDLER A, BURRIS H et al.: A Phase II study T138067-sodium in prior taxane-treated patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSVLC). 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 1282.
146. BECKMANN H, SANTHA E, LADD A, PARKA, HOUZE J, BAICHWAL V. Selective, covalent modification of certain β-tubulin isotypes by T900607, a novel antitumor agent with efficacy against multidrug resistant tumors. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1920.
147. SCHWENDER SW, HOFFMAN LA, THOOLEN MJ, CHOU TC, TIMMERMANS PB: Efficacy of the novel tubulin binding agent, T900607, against human tumor xenografts in mice. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1919.
148. SCHWENDER SW, HOFFMAN LA, THOOLEN MJ, TIMMERMANS PB: Efficacy of combination therapy with the tubulin binding agent, T900607, aaginst MX-1 human mammary tumor xenografts in mice. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1914.
149. WRIGHT MR, YE Q, THOOLEN MJ, KYNCH HD, STEIN CK, TIMMERMANS PB: Pharmacokinetics of T900607 in preclinical species. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1921.
150. CASSIDY J, KILLHAM P, ASIF-SULEMAN S, GIORDANO H, LEVY M, CARMICHAEL J: A Phase I study of T900607-sodium administered weekly in patients with refractory cancer. 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 416.
151. LOCKHART AC, MANI S, OLSEN R et al.: T900607-sodium administered daily x 5 as a 60-minute infusion every 3 weeks: a Phase I studt of T900607-sodium in patients (pts) with refractory cancer. 38th Annual Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 417.
152. MEDINA JC, DEXTER DW, BAICHWAL V et al.: Efficacy of T138067 and its analogs against resistant tumor cells that express the MDR1 drug pump, have mutation on β-tubulin, or changes in β-tubulin isotype expression patterns. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1378.
153. RUBENSTEIN SM, BAICHWAL V, BECKMANN H et al.: Hydrophilic, prodrug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. (2001) 44:3599-3605.
154. LEGAULT J, JEAN-FRANCOIS G, MOUNETOU E et al.: Microtubule distribution induced in vivo by alkylating of β-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res. (2000) 60:985-992.
155. MOUNETOU E, LEGAULT J, LACROIX J,: Antimitotic antitumor agents: synthesis, structure-activity relationships, and biological characterization of N-aryl-N-(2-chloroethyl)ureas as new selective alkylating agents. J. Med. Chem. (2001) 44:694-702.
156. JIANG JD, DAVIS AS, MIDDLETON K et al.: 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerisation, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res. (1998) 58:5389-5395.
157. JIANG JD, WANG Y, ROBOZ J, STRAUCHEN J, HOLLAND JF, BEKESI JG: Inhibition of microtubule assembly in tumour cells by 3-bromoacetylamino benzoyurea, a new cancericidal compound. Cancer Res. (1998) 58:2126-2133.
158. PINNEY KG, BOUNDS AD, DINGEMAN KM et al.: A new antitubulin agent containing the benzo[b]thiophene ring system. Bioorg. Med. Chem. Lett. (1999) 9:1081-1086.
159. CHEN Z, MOCHARLA VP, FARMER JM, PETTIT GR, HAMEL E, PINNEY KG: Preparation of new antitubulin ligands through a dual-mode, addition-elimination reaction to a bromosubstituted α,β-unsaturated sulfoxide. J. Org. Chem. (2000) 65:8811-8815.
160. MULLICA DF, PINNEY KG, MOCHARLA VP, DINGEMAN KM, BOUNDS AD, SAPPENFILED EL: Characterization and structural analyses of trimethoxy and Triethoxybenzo[b]thiophene. J. Chem. Crystallography (1998) 28:289-295.
161. PEYROT V, LEYNADIER D, SARRAZIN M et al.: Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: equilibrium studies. Biochem. (1992) 31:11125-11132.
162. DUCKI S, FORREST R, HADFIELD JA et al.: Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. (1998) 8:1051-1056.
163. LAWRENCE NJ, MCGOWN AT, DUCKI S, HADFIELD JA: The interaction of chalcones with tubulin. Anti-Cancer Drug Des. (2000) 15:135-141.
164. XIA Y, YANG Z, XIA P, BASTOW KF, NAKANISHI Y, LEE KH: Antitumor agents. Part 202: novel 2′-amino chalcones: design, synthesis and biological evaluation. Bioorg. Med Chem. Lett. (2000) 10:699-701.
165. TATSUMI Y, ARIOKA H, IKEDA S et al.: Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6. Jpn. J. Cancer Res. (2001) 92:768-777.
166. KANOH K, KOHNO S, ASARI T et al.: (-)- Phenylahistin - a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg. Med. Chem. Lett (1997) 7:2847-2852
167. KANOH K, KOHNO S, KATADA J, HAYASHI Y, MURAMATSU M, UNO I: Antitumor activity of phenylahistin in vitro and in vivo. Biosci. Biotechnol. Biochem. (1999) 63:1130-1133.
168. KANOH K, KOHNO S, KATADA J, TAKAHASHI J, UNO I: (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerisation. J. Antibiot. (1999) 52:134-141.
169. KANOH K, KOHNO S, KATADA J, TAKAHASHI J, UNO I, HAYASHI Y: Synthesis and biological activities of phenylahistin derivatives. Bioorg. Med. Chem. (1999) 7:1451-1457.
170. HAYASHI Y, ORIKASA S, TANAKA K, KANOH K, KISO Y: Total synthesis of anti-microtubule diketopiperazine derivatives: phenylahistin and aurantiamine. J. Org. Chem. (2000) 65:8402-8405.
171. USUI T, KONFOH M, CUI C, MAYUMI T, OSADA H: Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem. J. (1998) 333:543-548.
172. SANZ-CERVERA JF, STOCKING EM, USUI T, OSADA H, WILLIAMS RM: Synthesis and evaluation of microtubule assembly inhibition and cytotoxicity of prenylated derivatives of cyclo-L-Trp-L-Pro. Bioorg. Med. Chem. (2000) 8:2407-2415.
173. ZHAO S, SMITH KS, DEVEAU AM et al.: Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. J. Med. Chem. (2002) 45:1559-1562.
174. GOLUBOFF ET: Exisulind, a selective apoptotic antineoplastic drug. Exp. Opin. Invest. Drugs (2001) 10:1875-1882.
175. BUNN PA Jr, CHAN DC, EARLE K et al.: Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin. Oncol. (2002) 29:87-94.
176. THOMPSON WJ, PIAZZA GA, LI H et al.: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. (2000) 60:3338-3342.
177. SOH JW, MAO Y, KIM MG et al.: Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res. (2000) 6:4136-4141.
178. FETTER JR. WHITEHEAD C, YOON J-T et al.: G2/M cell cycle arrest by the pro-apoptotic cGMP phosphodiesterase inhibitor, CP248, in SW480 colon cancer cells involves inhibition of tubulin polymerisation via the colchicine binding site. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 1319.
179. LIM JT, PIAZZA GA, HAN EK et al.: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. (1999) 58:1097-1107.
180. LISOWSKI V, ENGUEHARD C, LANCELOT J et al.: Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. Bioorg. Med. Chem. Lett. (2001) 11:2205-2208.
181. CHEN X, PINE P, KNAPP AM, TUSE D, LADEROUTE KR: Oncocidin A1: a novel tubulin-binding drug with antitumor activity against human breast and ovarian carcinoma xenografts in nude mice. Biochem. Pharmacol. (1998) 56:623-633.
182. KUN E, MENDELEYEV J: Molecular pharmacology of methyl-3,5-diiodo-4 (4′-methoxyphenoxy) benzoate (DIME) and its non-hydrolyzible ethanone analog (DIPE) (Review). Int. J. Mol. Med. (1998) 2:585-590.
183. SHAN SQ, LOCKHART AC, SAITO WY, KNAPP AM, LADEROUTE KR, DEWHIRST MW: The novel tubulin-binding drug BTO-956 inhibits R3230Ac mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin. Cancer Res. (2001) 7:2590-2596.
184. NAITO H, SUGIMORI M, MITSUI I et al.: Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. Chem. Pharm. Bull. (Tokyo) (1999) 47:1679-1684.
185. IWAHANA M, OCHI Y, EJIMA A. Antiproliferative activity and mechanism of action of DZ-33 58, a novel pyrimidinyl pyrazole derivative. Anticancer Res. (2000) 20:785-792.
186. NAITO H, OHSUKI S, SUGIMORI M et al.: Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. optimisation of the phenylpiperazine moiety of 1-[5-mediyl-1 -(2-pyrimidinyl) -4-pyrazolyl]- 3-phenylpiperainyl -1-transpropenes. Chem. Pharm. Bull. (Tokyo) (2002) 50:453-462.
187. GÜNTHER EG, EMIG P, BAASNER S, SCHMIDT P, AUE B, POLYMEROPOULOS E: 1-Phenyl-4 -piperazinyl-carbonyl -substituted heterocyclic derivatives-a new class of highly potent compounds with inhibitory effects on the tubulin polymerisation. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 3654.
188. DE INES C, LEYNADIER D, BARASOAIN I et al.: Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res. (1994) 54:75-84.
189. ROWINSKY EK, LONG GS, NOE DA et al.: Phase I and pharmacological study of CI-980, a novel synthetic antimicrorubule agent. Clin. Cancer Res. (1997) 3:401-407.
190. BERNSTEIN ML, BARUCHEL S, DEVINE S et al.: Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J. Pediatr Hematol. Oncol. (1999) 21:494-500.
191. SKLARIN NT, LATHIA CD, BENSON L et al.: A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest. New Drugs (1997) 15:235-246.
192. THOMAS JP, MOORE T, KRAUT EH, BALCERZAK SP, GALLOWAY S, VANDRE DD: A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. (2002) 20:192-198.
193. WHITEHEAD RP, UNGER JM, FLAHERTY LE et al.: Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest. New Drugs (2001) 19:239-243.
194. PATEL SR, BURGESS MA, PAPADOPOLOUS NE et al.: Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest. New Drugs (1998) 16:87-92.
195. KUDELKA AP, HASENBURG A, VERSCHRAEGEN CF et al.: Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs (1998) 9:405-409.
196. PAZDUR R, MEYERS C, DIAZ-CANTON E et al.: Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic coloreccal carcinoma. Model for prospective evaluation of neurotoxicity. Am. J. Clin. Oncol. (1997) 20:573-576.
197. IMBERT TF: Discovery of podophyllotoxins. Biochim. (1998) 80:207-222.
198. VERDIER-PINARD P, LAI JY, YOO HD et al.: Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol. (1998) 53:62-76.
199. VERDIER-PINARD P, SITACHITTA N, ROSSI JV, SACKETT DL, GERWICK WH, HAMEL E: Biosynthesis of radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin. Arch. Biochem. Biophy. (1999) 370:51-58.
200. WIPF P, REEVES JT, BALACHANDRAN R, DAY BW: Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. J. Med. Chem. (2002) 45:1901-1917.
201. COMBEAU C, PROVOST J, LANCELIN F et al.: RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors. Mol. Pharmacol. (2000) 57:553-563.
202. CUSHMAN M, HE HM, KATZENELLENBOGEN JA, LIN CM, HAMEL E: Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerisation by binding to the colchicine binding site. J. Med. Chem. (1995) 38:2041-2049.
203. MILLER TA, BULMAN AL, THOMPSON CD, GARST ME, MACDONALD TL: Synthesis and structure-activity profiles of A-homoestranes, the estratropones. J. Med. Chem. (1997) 40:3836-3841.
204. CUSHMAN M, HE HM, KATZENELLENBOGEN JA et al.: Synthesis of analogs of 2-mcthoxyestradiol with enhanced inhibitory effects on tubulin polymerisation and cancer cell growth. J. Med. Chem. (1997) 40:2323-2334.
205. WANG Z, YANG D, MOHANAKRISHNAN AK et al.: Synthesis of B ring homologated estradiol analogues that modulate tubulin polymerisation and microtubule stability. J. Med. Chem. (2000) 43:2419-2429.
206. NICHOLSON KM, PHILLIPS RM, SHNYDER SD, BIBBY MC: In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. Eur. J. Cancer (2002) 38:194-204.
207. HILL BT: Vinflunine, a second generation novel Vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockcrs. Curr. Pharm. Des. (2001) 7:1199-1212.
208. LOBERT S, CORREIA JJ: Energetics of Vinca alkaloid interactions with tubulin. Methods Enzymol. (2000) 323:77-103.
209. SHIH C, TEICHER BA: Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr. Pharm. Des. (2001) 7:1259-1276.
210. ROWINSKY EK, DONEHOWER RC: Antimitotic agents. In: Cancer: Principles and Practice of Oncology DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia (1997):468-472.
211. FAHY J: Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr. Pharm. Des. (2001) 7:1181-1197.
212. GREGORY RK, SMITH I: Vinorelbine-a clinical review. Br. J. Cancer (2000) 82:1907-1913.
213. SCHWARTZ GN, BONG D, LEICHMAN CG, LEICHMAN LL: Phase I evaluation of anhydrovinblastine in patients with advanced malignancies. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 3895.
214. RAMNATH N, SCHWARTZ GN, BOOKER B et al.: A Phase I and pharmacokinetic study of anhydrovinblastine. 38th Annual Meeting of American Society of Clinical Ontology Orlando, USA (2002): Abstract 421.
215. KRUCZYNSKI A, HILL BT: Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Critical Rev. Oncology-Hematology (2001) 40:159-173.
216. LOBERT S, INGRAM JW, HILL BT, CORREIA JJ: A comparison of thermodynamic parameters for vinorelbine-and vinflunine-induced tubulin self-association by sedimentation velocity. Mol. Pharmacol. (1998) 53:908-915.
217. FUMOLEAU P, RAYMOND E, BENNOUNA J et al.: Phase I trial of vinflunine (L0070) a novel fluorinated Vinca alkaloid in patients (pts) with advanced solid malignancies: final results. 92nd Annual Meeting of American Association for Cancer Research. Orlando, USA (2001): Abstract 4478.
218. KRUCZYNSKI A, RICOME C, ASTRUC J et al.: Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon liver metastases by vinflunine, the most recent Vinca alkaloid in clinical development. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 1332.
219. COMIN-ANDUIX B, AGELL N, BACHS O, OVADI J, CASCANTE M: A new bis-indole, KARs, induces selective M arrest with specific spindle aberration in neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. (2001) 60:1235-1242.
220. CORBETT TH, VALERIOTE FA, DEMCHIK L et al.: Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest. New Drugs (1997) 15:207-218.
221. PANDA D, DELUCA K, WILLLAMS D, JORDAN MA, WILSON L: Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microrubule ends. Proc. Natl. Acad. Sci. USA (1998) 95:9313-9318.
222. PANDA D, ANANTHNARAYAN V, LARSON G, SHIH C, JORDAN MA, WILSON L: Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochem. (2000) 39:14121-14127.
223. LU K, DEMPSEY J, SCHULTZ RM, SHIH C, TEICHER BA: Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells. Cancer Chemother. Pharmacol. (2001) 47:170-178.
224. EGGEN M, GEORG GI: The cryptophycins: their synthesis and anticancer activity. Med. Res. Rev. (2002) 22:85-101.
225. GOTH G, SCHOTT K, OHNMACHT U, MANEGOLD C, GATZEMEIER U: A Phase II study of LY355703 (cryptophycin) as first-line therapy for stage IIIb or IV NCSLC subjects: preliminary analysis. Eur. J. Cancer (2001) 37:S48.
226. HAUSNER PF, EDELMAN MJ, DESANTO J, DOYLE LA, GRANDARA DR, ISRAEL V: Salvage therapy with cryptophycin-52 (C52) in platinum-treated non-small cell lung cancer (NSCLC). 38th Annud Meeting of American Society of Clinical Oncology. Orlando, USA (2002): Abstract 2688.
227. MUNRO MH, BLUNT JW. DUMDEI EJ et al.: The discovery and development of marine compounds with pharmaceutical potential. J. Biotechnol. (1999) 70:15-25.
228. TOWLE MJ, SALVATO KA, BUDROW J et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. (2001) 61:1013-1021.
229. TOWLE MJ, SALVATO KA, BUDROW J et al.: In vivo anticancer activity of synthetic halichondrin B macrocyclic ketone analogs ER-076349 and ER-086526 correlates with ability to induce irreversible mitotic blocks. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001). Abstract 1976.
230. VEDEJS E, KONGKITTINGAM C: A total synthesis of (-)-hemiasterlin using N-Bts methodology. J. Org. Chem. (2001) 66:7355-7364.
231. GAMBLE WR, DURSO NA, FULLER RW et al.: Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg. Med. Chem. (1999) 7:1611-1615.
232. BAI R, DURSO NA, SACKETT DL, HAMEL E: Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochem. (1999) 38:14302-14310.
233. ZASK A, BIRNBURG G, CHEUNG K et al.: Synthesis and biogical activity of analogs of the and microtubule agent HTI-286. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 3653.
234. LOGANZO F, DISCAFANI C, ANNABLE T et al.: HTI-286, a synthetic analog of the antimicrotubule tripeptide hemiasterlin, potently inhibits growth of cultured tumor cells, overcomes resistance to paclitaxel mediated by various mechanisms, and demonstrates intravenous and oral in vivo efficacy. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002)-Abstract 1316.
235. PONCET J: The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des. (1999) 5:139-162.
236. KALEMKERIAN GP, OU X, ADIL MR et al.: Accivity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother: Pharmacol. (1999) 43:507-515.
237. WATANABE J, NATSUME T, FUJIO N, MIYASAKA K, KOBAYASHI M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis (2000) 5:345-353.
238. AHERNE GW, HARDCASTLE A, VALENTI M et al.: Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother. Pharmacol. (1996) 38:225-232.
239. TOPPMEYER DL, SLAPAK CA, CROOP J, KUFE DW: Role of P-glycoprotein in dolastatin 10 resistance. Biochem. Pharmacol. (1994) 48:609-612.
240. THAMM DH, MACEWEN EG, PHILLIPS BS et al.: Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother. Pharmacol. (2002) 49:251-255.
241. WRIGHT JJ, BLATNER G, CHESON BD: Clinical trials referral resource. Clinical trials of dolastatin-10. Oncol (Huntington) (1999) 13:68-70.
242. KRUG LM, MILLER VA, KALEMKERIAN GP et al.: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals Oncol. (2000) 11:227-228.
243. YAMAMOTO N, ANDOH M, KAWAHARA M, FUKUOKA M, NIITANI H: Phase I study of TZT-1027, an inhibitor of tubulin polymerisation, given weekly x 3 as a 1-hour intravenous infusion in patients (PTS) with solid tumors. 38th Annual Meeting of American Society of Clinical Oncology. Onlardo, USA (2002)-Abstract 420.
244. HORTI J: Preliminary result of a Phase I trial of TZT-1027, an inhibitor of tubulin polymerisation, in patients with advanced non-small cell lung cancer. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 2744.
245. NO AUTHORS LISTED: TZT-1027. Drugs Fut. (1999) 24:404-409.
246. HU MK, HUANG WS: Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15. J. Peptide Res. (1999) 54:460-467.
247. DE ARRUDA M, COCCHIARO CA, NELSON CM et al.: LU103793 (NSC D669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res. (1995) 55:3085-3092.
248. SMYTH J, BONETERRE ME, SCHELLENS J et al.: Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann. Oncol, (2001) 12:509-511.
249. NELSON CM, CONLON D, SMITH PA et al.: Preclinical pharmacology of LU223651, orally available analog of cemadotin HCl. 90st Annual Meeting of American Association for Cancer Research. Philadelphia, USA (1999):Abstract 1908.
250. NICOLETTI MI, TURATTO M, MARTINELLI M, RARLOZZARI T, GIAVAZZI R. Oral antitumor activity of dalastatin 15 analog, LU223651, against human ovarian carcinoma xenografts. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000):Abstract 1927.
251. MICHAELSON MD, RYAN DP, FRAM R et al.: A Phase I clinical trial of ILX651, a dolastatin-15 analog, administered as a 30-minute intravenous infusion every other day x 3 doses every 21 days in patients with advanced solid tumors. 38th Annual Meeting of American Association of Clinical Research. Orlando, USA (2002):Abstract 414.
252. EBBINGHAUS SW, DUNN H, JENNINGS L, DIJK SV, FRAM R:A Phase I and pharmacokinetic study of the dolastatin 15 analog ILX651. 38th Annual Meeting of American Association of Clinical Research Orlando, USA (2002):Abstract 1743.
253. YE K, KE Y, KESHAVA N et al.: Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad Sci. USA (1998) 95:1601-1606.
254. YE K, ZHOU J, LANDEN JW, BRADBURY EM, JOSHI HC: Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis. J. Biol. Chem. (2001) 276:46697-46700.
255. SCHULER M, MUEHLBAUER P, GUZZIE P, EASTMOND DA: Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes. Mutagenesis (1999) 14:51-56.
256. LANDEN JW ARCHER DR, DAVIS TP, WAINER BH, JOSHI HC: The microtubule inhibitor noscapine for the treatment of glioblastoma in immunodefficient mice. 92nd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000):Abstract 1361.
257. CHANG Y-T, WIGNALL SM, ROSANIA GR et al.: Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J. Med. Chem. (2001) 44:4497-4500.
258. ROSANIA GR, CHANG Y-T, PEREZ O et al.: Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol. (2000) 18:304-308.
259. UCKUN FM: Rationally designed antimitotic agents with pro-apoptotic activity. Curr. Pharm. Des. (2001) 7:1627-1639.
260. UCKUN FM, MAO C, JAN ST et al.: Spongistatins as tubulin targeting agents. Curr. Pharm. Des. (2001) 7:1291-1296.
261. JAN ST, MAO C, VASSILEV AO, NAVARA CS, UCKUN FM: COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerising activity as a novel anticancer agent. Bioorg. Med. Chem. Lett. (2000) 10:1193-1197.
262. FLORSHEIMER A, ALTMANN KH: Epothilones and their analogues - a new class of promising microtubule inhibitors. Exp. Opin. Ther. Patents (2001) 11:951-968.
263. JORDAN MA, TOSO RJ, THROWER D, WILSON L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA (1993) 90:9552-9556.
264. BERGNES G, HA ED, FENG B et al.: Mitotic kinesin-targeted antitumour agents: discovery, lead optimisation and anti-tumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 3648.
265. JOHNSON RK, MCCABE FL, CAUDER E et al.: SB-715992, a potent and selective inhibitor of KSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 1335.